As TAVI Advances, Adjunctive Devices Multiply
As researchers work to more fully understand the risks and durability of transcatheter aortic heart valve implantation (TAVI) procedures, device innovators are already attempting to engineer solutions to some of the more obvious areas of unmet need.
You may also be interested in...
Brief summaries of recent medtech market and industry developments. This month we cover KCI's shift to private status, J&J's exit from drug-eluting stents, safety concerns about Edwards' Sapien TAVI device, and the MoneyTree 2Q2011 report on medtech venture financings.
Another blow-out quarter from Pfizer provided the impetus for an acquisition. But the history of recent commercial-stage biotech transactions and the risky nature of all early-stage companies suggest that the floodgates will not burst open.
EU Business News: PharmaSGP Makes Record Start, BioGaia Heads To Canada, Ardian Takes Nutripure Stake
Round-up of European consumer health business news: Germany's PharmaSGP breaks sales record in Q1 as acquired brands grow; probiotics player BioGaia plans direct distribution in Canada; and private-equity firm Ardian takes a stake in French e-commerce supplements specialist Nutripure.